Literature DB >> 4838913

Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

J D Parkes, R C Baxter, C D Marsden, J E Rees.   

Abstract

Fourteen slightly disabled patients with Parkinsonism were treated separately with benzhexol, amantadine, and levodopa. Benzhexol and amantadine both gave a 15% reduction in functional disability and levodopa a 36% reduction. Benzhexol lessened the rigidity and improved the flexion of posture of Parkinson's disease, but had little or no effect on akinesia and tremor. Amantadine and levodopa caused improvement in all these symptoms. The combination of benzhexol and amantadine was as effective after four weeks of treatment as levodopa was after six months.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4838913      PMCID: PMC494673          DOI: 10.1136/jnnp.37.4.422

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  On the mode of action of amantadine.

Authors:  U Stromberg; T H Svensson; B Waldeck
Journal:  J Pharm Pharmacol       Date:  1970-12       Impact factor: 3.765

2.  Cholinergic-anticholinergic antagonism in parkinsonism.

Authors:  R C Duvoisin
Journal:  Arch Neurol       Date:  1967-08

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  The continued use of amantadine hydrochloride in parkinsonism.

Authors:  D B Appleton; M J Eadie; J M Sutherland
Journal:  Med J Aust       Date:  1971-10-02       Impact factor: 7.738

5.  L-dopa and amantadine hydrochloride in Parkinson's disease.

Authors:  J D Parkes; K J Zilkha; R P Knill-Jones; P J Clements; R Baxter
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1971-04

6.  Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England
Journal:  Trans Am Neurol Assoc       Date:  1969

7.  Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.

Authors:  B Scatton; A Cheramy; M J Besson; J Glowinski
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

8.  Amantadine in Parkinsonism.

Authors:  J Pearce; N S Rao
Journal:  Lancet       Date:  1970-11-21       Impact factor: 79.321

9.  Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.

Authors:  D B Calne; J L Reid; S D Vakil; S Rao; A Petrie; C A Pallis; J Gawler; P K Thomas; A Hilson
Journal:  Br Med J       Date:  1971-09-25

10.  Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs.

Authors:  R C Hughes; J G Polgar; D Weightman; J N Walton
Journal:  Br Med J       Date:  1971-05-29
View more
  6 in total

Review 1.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

Review 2.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

3.  A minimally invasive neurostimulation method for controlling abnormal synchronisation in the neuronal activity.

Authors:  Malbor Asllani; Paul Expert; Timoteo Carletti
Journal:  PLoS Comput Biol       Date:  2018-07-19       Impact factor: 4.475

4.  Novel antitumor adamantane-azole gold(I) complexes as potential inhibitors of thioredoxin reductase.

Authors:  Adriana Garcia; Rafael Carvalhaes Machado; Richard Michael Grazul; Miriam Teresa Paz Lopes; Charlane Cimini Corrêa; Hélio F Dos Santos; Mauro Vieira de Almeida; Heveline Silva
Journal:  J Biol Inorg Chem       Date:  2016-02-03       Impact factor: 3.358

5.  Experimental and theoretical investigation of cyclometallated platinum(ii) complex containing adamantanemethylcyanamide and 1,4-naphthoquinone derivative as ligands: synthesis, characterization, interacting with guanine and cytotoxic activity.

Authors:  Leila Tabrizi; Bachir Zouchoune; Abdallah Zaiter
Journal:  RSC Adv       Date:  2019-01-02       Impact factor: 4.036

Review 6.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.